MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: Comparison of triple negative breast cancer and other intrinsic subtypes

Breast Cancer

Volumn 18, Issue 3, 2011, Pages 152-160

  Nakahara, Hiroshi ^a   Yasuda, Yukiko ^a   Machida, Eiichiro ^a   Maeda, Yorio ^a   Furusawa, Hidemi ^a   Komaki, Kansei ^a   Funagayama, Mayumi ^a   Nakahara, Mayumi ^b   Tamura, Shozo ^b   Akiyama, Futoshi ^c  

^a Breastopia Medical Corporation   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Magnetic resonance imaging; Neoadjuvant chemotherapy; Pathology; Triple negative breast cancer; Ultrasonography

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXIFLURIDINE; EPIRUBICIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; ECHOMAMMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; ULTRASONOGRAPHY, MAMMARY;

EID: 81855163411     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-010-0235-4     Document Type: Article

References (33)

1. Fisher B, Bryant J, Wolmark N,Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome ofwomen with operable breast cancer. J Clin Oncol. 1998;16:2672-85.
2. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82:1539-45.
3. Calais G, Berger C, Descamps P, Chapet S, Reynaud-Bougnoux A, Body G, et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer. 1994;74:1283-8.
4. Calais G,Descamps P, Chapet S, TurgeonV,Reynaud-BougnouxA, Lemarie E, et al. Primary chemotherapy and radiosurgical breastconserving treatment for patients with locally advanced operable breast cancers. Int J Radiat Oncol Biol Phys. 1993;26:37-42.
5. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988;62:2507-16.
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
7. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-68.
8. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18:1927-34.
9. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814-9.
10. Loibl S, von Minckwitz G, Raab G, Blohmer JU, Dan Costa S, Gerber B, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13:1434-42.
11. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-85.
12. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008;26:246-52.
13. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414-22.
14. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Outlaw ED, Strom EA, et al. Breast conservation after neoadjuvant chemotherapy. Cancer. 2005;103:689-95.
15. Beriwal S, Schwartz GF, Komarnicky L, Garcia-Young JA. Breast-conserving therapy after neoadjuvant chemotherapy: longterm results. Breast J. 2006;12:159-64.
16. Garimella V, Qutob O, Fox JN, Long ED, Chaturvedi A, Turnbull LW, et al. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol. 2007;33:157-61.
17. Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2010;119:551-8.
18. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13: 2329-34.
19. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-81.
20. Gilles R, Guinebretiere JM, Toussaint C, Spielman M, Rietjens M, Petit JY, et al. Locally advanced breast cancer: contrastenhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology. 1994;191:633-8.
21. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am J Roentgenol. 2002;179:1193-9.
22. Belli P, Costantini M, Malaspina C, Magistrelli A, Latorre G, Bonomo L. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol. 2006;61:946-53.
23. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004;14:1371-9.
24. Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am J Roentgenol. 2005;184:868-77.
25. Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, et al.Accuracy ofMRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol. 2003;181:1275-82.
26. Straver ME, Loo CE, Rutgers EJ, Oldenburg HS, Wesseling J, Vrancken Peeters MJ, et al. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg. 2010;251:701-7.
27. Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol. 1992;19:278-85.
28. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer. 1992;69:2849-52.
29. Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008;112:17-26.
30. Chen JH, Feig BA, Hsiang DJ, Butler JA, Mehta RS, Bahri S, et al. Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer. Ann Surg. 2009;249:448-54.
31. Akiyama F, Iwase H. Triple negative breast cancer: clinicopathological characteristics and treatment strategies. Breast Cancer. 2009;16:252-3.
32. Sasaki Y, Tsuda H. Clinicopathological characteristics of triplenegative breast cancers. Breast Cancer. 2009;16:254-9.
33. Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H. Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer. 2009;16:260-7.